Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck Kgaa ADR (OP: MKKGY )

33.78 +0.07 (+0.21%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,672
Open 33.61
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 33.71
Today's Range 33.61 - 33.96
52wk Range 28.59 - 38.26
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition
Pfizer Inc (NYSE: PFE)  
Via Benzinga
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
Merck KGaA (OTC: MKGAF) (OTC:  
Via Benzinga

Performance

YTD
+8.58%
+8.58%
1 Month
-8.55%
-8.55%
3 Month
+5.56%
+5.56%
6 Month
+5.69%
+5.69%
1 Year
+0.96%
+0.96%

More News

Read More
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
Via Benzinga
Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023
Via Benzinga
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
Via Benzinga
Germany's Merck To Launch Semiconductor Base In China
Via Benzinga
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
Via Benzinga
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
Via Benzinga
FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study
Via Benzinga
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
Via Benzinga
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
Via Benzinga
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Via Benzinga
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment
Via Benzinga
Mersana Inks Cancer Therapy Development Deal With Merck Germany
Via Benzinga
SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19
Via Benzinga
Germany's Merck Slapped With Formal French Investigation Related To Its Thyroid Drug
Via Benzinga
PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers
Via Benzinga
TSM Looks To Hire Over 8,000 People In 2022
Via Benzinga
Despite Palantir’s Impressive Deals, Its Losses and Valuation Make It Unappetizing
Via InvestorPlace
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Via Benzinga
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
Via Benzinga
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
Via Benzinga
Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
Via Benzinga
Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck
Via Benzinga
Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.